PROJECT 2 Project 2 of the CREATE RDCRC will explore the genetic determinants of ALS and related disorders using a novel and innovative approach in which we capitalize on shared phenotypic elements across this group of disorders. For Project-2 we will enroll and deeply phenotype 500 patients with ALS and related disorders in whom the genetic cause of disease is not currently known. These data will be combined with the deep phenotypic data collected on 200 patients with ALS and related disorders in which the primary genetic cause has already been identified (Project-1). Genetic studies will identify novel genes for ALS and related disorders, and begin to illuminate the factors that modify the natural course of disease and define endophenotypic features/phenotypic elements that cut cross the boundaries of classic disease entities. This will be achieved by examining both common and rare variation in the context of novel gene discovery in familial and sporadic cases and genetic modifiers in the case of established genetic mutations. All genetic analyses will be based on whole exome sequencing and genome-wide array genotyping as a backbone for the genetic architecture of each sample. In addition to the ~700 exomes we will generate from our deeply phenotyped cohort, we have or expect to have access to ~2,500 exomes from patients with ALS and related disorders, which will be used to confirm/validate the findings in our cohort.

Public Health Relevance

The genetic factors identified in our studies will enhance our ability to predict disease onset, course and outcome;will help guide molecular and drug discovery studies;and will be critical to the success of our future efforts to undertake clinical trials in genetically defined populations. This study will also lay a foundation of deep phenotypic and deep genetic data for use by the broader research community.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Gubitz, Amelie
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Miami School of Medicine
Coral Gables
United States
Zip Code
Nicolas, Aude (see original citation for additional authors) (2018) Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97:1268-1283.e6
Wilke, Carlo; Rattay, Tim W; Hengel, Holger et al. (2018) Serum neurofilament light chain is increased in hereditary spastic paraplegias. Ann Clin Transl Neurol 5:876-882
Lassuthova, Petra; Rebelo, Adriana P; Ravenscroft, Gianina et al. (2018) Mutations in ATP1A1 Cause Dominant Charcot-Marie-Tooth Type 2. Am J Hum Genet 102:505-514
Chen, Jacqueline; Kostenko, Volodymyr; Pioro, Erik P et al. (2018) MR Imaging-based Estimation of Upper Motor Neuron Density in Patients with Amyotrophic Lateral Sclerosis: A Feasibility Study. Radiology 287:955-964
Pottier, Cyril; Rampersaud, Evadnie; Baker, Matt et al. (2018) Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report. Amyotroph Lateral Scler Frontotemporal Degener 19:469-471
Prudencio, Mercedes; Gonzales, Patrick K; Cook, Casey N et al. (2017) Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients. Hum Mol Genet 26:3421-3431
Jacquier, Arnaud; Delorme, C├ęcile; Belotti, Edwige et al. (2017) Cryptic amyloidogenic elements in mutant NEFH causing Charcot-Marie-Tooth 2 trigger aggresome formation and neuronal death. Acta Neuropathol Commun 5:55
Finch, NiCole A; Wang, Xue; Baker, Matthew C et al. (2017) Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurol Genet 3:e161
DeJesus-Hernandez, Mariely; Finch, NiCole A; Wang, Xue et al. (2017) In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathol 134:255-269
Gendron, Tania F; Chew, Jeannie; Stankowski, Jeannette N et al. (2017) Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med 9:

Showing the most recent 10 out of 23 publications